Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;87:1118-1122

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelband, C. H.
Right arrow Articles by Raizada, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelband, C. H.
Right arrow Articles by Raizada, M. K.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Genes and Gene Therapy
*High Blood Pressure
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Cell signalling/signal transduction
Right arrow Functional genomics
Right arrow Hypertension - basic studies
Right arrow Physiological and pathological control of gene expression
Right arrow Gene therapy
Right arrow Genetics of cardiovascular disease
(Circulation Research. 2000;87:1118.)
© 2000 American Heart Association, Inc.


MiniReview

Current Perspectives on the Use of Gene Therapy for Hypertension

Craig H. Gelband, Michael J. Katovich, Mohan K. Raizada

From the Department of Physiology, College of Medicine (C.H.G., M.K.R.) and Department of Pharmacodynamics, College of Pharmacy (M.J.K.), University of Florida, Gainesville, Fla.

Correspondence to Craig H. Gelband, PhD, Department of Physiology, University of Florida College of Medicine, PO Box 100274, Gainesville, FL 32610-0274. E-mail gelband{at}phys.med.ufl.edu

Abstract—Systemic hypertension is a pathophysiological state that is manifested as high blood pressure and is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage. Pulmonary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, or secondary pulmonary hypertension attributable to a variety of lung and cardiovascular diseases. This review discusses the use of gene therapy in the control of systemic and pulmonary hypertension. Overexpression of vasodilator genes as well as antisense knockdown of vasoconstrictor genes has been successfully used in animal models of both forms of hypertension. Furthermore, the use of viral vectors to deliver these constructs has achieved long-term control of hypertension. The successful establishment of gene therapy techniques in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension.


Key Words: antisense • gene therapy • hypertension • renal and cardiac pathophysiology • renin-angiotensin system




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J.-C. Richard, Z. Zhou, D. E. Ponde, C. S. Dence, P. Factor, P. N. Reynolds, G. D. Luker, V. Sharma, T. Ferkol, D. Piwnica-Worms, et al.
Imaging Pulmonary Gene Expression with Positron Emission Tomography
Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1257 - 1263.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
Y. Chu, S. Iida, D. D. Lund, R. M. Weiss, G. F. DiBona, Y. Watanabe, F. M. Faraci, and D. D. Heistad
Gene Transfer of Extracellular Superoxide Dismutase Reduces Arterial Pressure in Spontaneously Hypertensive Rats: Role of Heparin-Binding Domain
Circ. Res., March 7, 2003; 92(4): 461 - 468.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
K Taylor and J Stein
Dyslexia and familial high blood pressure: an observational pilot study
Arch. Dis. Child., January 1, 2002; 86(1): 30 - 33.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. S. Pachori, M. J. Huentelman, S. C. Francis, C. H. Gelband, M. J. Katovich, and M. K. Raizada
The Future of Hypertension Therapy: Sense, Antisense, or Nonsense?
Hypertension, February 1, 2001; 37(2): 357 - 364.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al.
Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?
Physiol Genomics, December 21, 2001; 7(2): 79 - 94.
[Abstract] [Full Text] [PDF]